myosin

Myosin V-IN-1 is a potent and selective inhibitor of Myosin V with a Ki value of 6 μM.Myosin V-IN-1 inhibits actin V and slows down actin-activated myosin V ATPase by selectively inhibiting the release of ADP from the actinoglobulin complex.

(-)-Blebbistatin ((S)-(-)-Blebbistatin) is an S enantiomer of blebbistatin. It is a potent and selective myosin II inhibitor with IC50 ranging from 0.5 to 5 μM.

JB002, a myosin II inhibitor, exhibits potent activity with an IC50 of ≤10 μM. It holds potential for research applications in muscle spasticity, chronic musculoskeletal pain, and hypertrophic cardiomyopathy.

JB061 is a nonmuscle myosin inhibitor, demonstrating selective inhibitory activity with IC50 values of 4.4 μM (Cardiac muscle myosin), 9.1 μM (Skeletal muscle myosin), and >100 μM (Smooth muscle myosin II). It exhibits limited efficacy in reducing ATPase activity, with an IC50 exceeding 200 μM. Furthermore, JB061 displays cytotoxic effects on COS-7 cells, evidenced by an IC50 value of 39 μM.

JB062 is a chemical compound acting as a nonmuscle myosin inhibitor, exhibiting IC50 values of 1.6, 5.4, and >100 μM against skeletal muscle myosin, cardiac muscle myosin, and smooth muscle myosin II, respectively. It selectively exhibits cytotoxicity towards human cancer cells without affecting normal cells. The compound is applicable in research fields concerning muscle spasticity, chronic musculoskeletal pain, and hypertrophic cardiomyopathy.

Myosin H Chain Fragment, mouse acetate salt, a segment of the α-Myosin heavy chain peptide, is crucial for developing the experimental autoimmune myocarditis (EAM) mouse model [1] [2].

Myosin light chain kinase fragment 11-19 amide (MLCK(11-19) amide) acts as a substrate-specific peptide inhibitor of MLCK and inhibits hypotonicity-induced Ca2+ entry, with applications in human cervical cancer research [1] [2].

Myosin H Chain Fragment, mouse, is a segment of the α-Myosin heavy chain peptide and serves as an inducer of experimental autoimmune myocarditis (EAM) in mouse models [1] [2].

Myosin-IN-1 (compound F10), a specific inhibitor of cardiac myosin, acts by stabilizing the cardiac myosin motor domain in its closed biochemical and structural state. It reduces myocardial force production and calcium sensitivity, functioning as a negative inotropic agent. In isolated Langendorff-perfused rat hearts, Myosin-IN-1 decreases stress in myofilaments and diminishes the development of left ventricular pressure. This compound is applicable in heart failure research [1].

Myosinmodulator 2 (Compound B172) is a myosin modulator that can inhibit ATPase activity in rabbit psoas muscle, pig atrium, and pig ventricle with IC25 values of 2.013, 2.94, and 20.93 μM, respectively. Additionally, Myosinmodulator 2 influences cardiac contractility in Sprague Dawley rats.

Adhibin is an allosteric inhibitor of RhoGAP class IX myosin (RhoGAP class IXmyosin), effectively inhibiting Myo9 ATPase in both mammals and invertebrates with an IC50 of 2.5 µM and 2.6 µM, respectively. It binds to ATPase, disrupting myosin's motor functions, blocking RhoGTPase-related signaling pathways, and affecting cellular migration, adhesion, and division. Adhibin is applicable for research in cancer metastasis.

Ulacamten is an effective inhibitor of cardiac myosin (cardiacmyosin).

Nocarnickelamides B (Compound 2) is a linear peptide and an inhibitor of ROCK1 2. It exhibits dual inhibitory activity against ROCK1 and ROCK2, with IC50 values of 14.9 μM and 21.9 μM, respectively. This compound binds to the ATP binding site and inhibits ROCK-mediated cytoskeletal contraction markers, such as myosin light chain activation. Nocarnickelamides B can be utilized in glaucoma research.

Thymosin β4 (cattle) TFA is a high-affinity activator of MLCK that operates independently of Ca2+ [1].

ATM-3507 is a protomyosin inhibitor with anticancer activity that inhibits human melanoma and can be used to study ovarian cancer.

MS-444 (BE-34776) is a smooth muscle myosin light chain kinase (MLCK) and HuR inhibitor with antitumor activity for triple-negative breast and colorectal cancer.

para-Nitroblebbistatin is a non-cytotoxic, non-fluorescent, photostable, and specific inhibitor of myosin II. para-Nitroblebbistatin can be used to study the specific roles of myosin II in physiology, development, and cell biology.

BTS (N-Tosylbenzylamine) is a potent inhibitor of Ca2+-stimulated myosin S1 ATPase (IC50 : 5 μM) .

Mavacamten (MYK-461) is an orally bioavailable inhibitor of cardiac myosin ATPase,( IC50s of 490, 711 nM for bovine cardiac and human cardiac, respectively)

ML-7 hydrochloride (ML-7 HCl) is a cell-permeable, reversible, effective, ATP-competitive, and specific inhibitor of myosin light chain kinase (Ki: 300 nM); also inhibits smooth-muscle myosin light chain kinase, PKA, and PKC.

HA-100 is an inhibitor of protein kinase

ML-9 suppresses MLCK, PKA, and PKC activity with Ki values of 4, 32, and 54 μM, respectively. ML-9 is a selective and effective inhibitor of Akt kinase, inhibits myosin light-chain kinase (MLCK), and stromal interaction molecule 1 (STIM1) activity. ML-9 causes autophagy by stimulating autophagosome formation and inhibiting their degradation.

Danicamtiv (MYK-491) is an inotropic agent and it also is a selective allosteric activator of cardiac myosin. Danicamtiv increases cardiac systolic function and preserves mechanical efficiency.